396 related articles for article (PubMed ID: 9425399)
21. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
22. [Somatostatin analogs in the clinical management of pituitary neoplasms].
Colao A; Dorato M; Pulcrano M; Rossi FW; Auriemma RS; Lombardi G; Lastoria S
Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
[TBL] [Abstract][Full Text] [Related]
23. [New medical treatments in pituitary adenomas].
Drutel A; Caron P; Archambeaud F
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
[TBL] [Abstract][Full Text] [Related]
24. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas.
Plöckinger U; Albrecht S; Mawrin C; Saeger W; Buchfelder M; Petersenn S; Schulz S
J Clin Endocrinol Metab; 2008 Apr; 93(4):1203-10. PubMed ID: 18198230
[TBL] [Abstract][Full Text] [Related]
25. The role of somatostatin receptor scintigraphy in the management of pituitary tumours.
Moulik PK; Varma TR; Vora JP; Vinjamuri S
Nucl Med Commun; 2002 Feb; 23(2):117-20. PubMed ID: 11891464
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin receptors in GH-secreting pituitary adenomas--their relationship to the response to octreotide.
Pawlikowski M; Pisarek H; Kunert-Radek J; Radek M
Endokrynol Pol; 2008; 59(3):196-9. PubMed ID: 18615392
[TBL] [Abstract][Full Text] [Related]
27. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy.
Lamberts SW; Hofland LJ; de Herder WW; Kwekkeboom DJ; Reubi JC; Krenning EP
Front Neuroendocrinol; 1993 Jan; 14(1):27-55. PubMed ID: 8097480
[TBL] [Abstract][Full Text] [Related]
28. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
Pisarek H; Pawlikowski M; Kunert-Radek J; Winczyk K
Endokrynol Pol; 2010; 61(2):178-81. PubMed ID: 20464704
[TBL] [Abstract][Full Text] [Related]
29. Prediction of efficacy of octreotide therapy in patients with acromegaly.
Colao A; Ferone D; Lastoria S; Marzullo P; Cerbone G; Di Sarno A; Longobardi S; Merola B; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2356-62. PubMed ID: 8964877
[TBL] [Abstract][Full Text] [Related]
30. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
31. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
32. Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma.
George SR; Kovacs K; Asa SL; Horvath E; Cross EG; Burrow GN
Clin Endocrinol (Oxf); 1987 Apr; 26(4):395-405. PubMed ID: 2888549
[TBL] [Abstract][Full Text] [Related]
33. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.
Losa M; Magnani P; Mortini P; Persani L; Acerno S; Giugni E; Songini C; Fazio F; Beck-Peccoz P; Giovanelli M
Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757
[TBL] [Abstract][Full Text] [Related]
34. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
35. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
36. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
[TBL] [Abstract][Full Text] [Related]
37. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
Lucas T; Astorga R; Catalá M;
Clin Endocrinol (Oxf); 2003 Apr; 58(4):471-81. PubMed ID: 12641631
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
39. (99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy.
Colao A; Ferone D; Lombardi G; Lastoria S
Clin Endocrinol (Oxf); 2002 Jun; 56(6):713-21. PubMed ID: 12072040
[TBL] [Abstract][Full Text] [Related]
40. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]